Tuesday, Medtronic Plc (NYSE:MDT) reported first-quarter 2025 sales of $7.92 billion, beating the consensus of $7.89 billion. The medical device maker reported adjusted EPS of $1.23, beating the consensus of $1.20. Revenue increased 2.8% year over year, as reported, and 5.3% organic. The company said multiple franchises delivered, with accelerating growth in Cardiac Ablation Solutions and Neuromodulation and continued strength in Spine, Structural Heart, and Diabetes. Also Read: Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers. Cardiovascular segmen…
